Health-related quality of life, depressive symptoms, and chronic fatigue in long-term survivors of Hodgkin lymphoma

References

• Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;398(10310):1518–1527.
   PubMed Web of Science ®Google Scholar
• Myklebust T, Aagnes B, Nilssen Y, et al. Cancer survival in Norway 1965–2021: extending standard reporting to improve communication of survival statistics. Oslo: Cancer Registry of Norway; 2022.
   Google Scholar
• Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574–1583.
   PubMed Web of Science ®Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.
   PubMed Web of Science ®Google Scholar
• Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood. 2018;131(15):1689–1697.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Ng AK. Late sequelae in Hodgkin lymphoma survivors. Hematol Oncol. 2017;35(S1):60–66.
   PubMedGoogle Scholar
• Smeland K, Holte H, Fagerli U-M, et al. Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life. Haematologica. 2022;107(11):2698–2707.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–2511.
   PubMed Web of Science ®Google Scholar
• Kiserud CE, Fossa A, Holte H, et al. Post-treatment parenthood in Hodgkin’s lymphoma survivors. Br J Cancer. 2007;96(9):1442–1449.
   PubMed Web of Science ®Google Scholar
• Lang N, Crump M. PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma. Ther Adv Hematol. 2020;1:1–15.
   Google Scholar
• Vellemans H, André MPE. Review of treatment options for the management of advanced stage Hodgkin lymphoma. Cancers. 2021;13(15):3745.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, André M, Johnson P, et al. Controversies in the treatment of classical Hodgkin lymphoma. Hemasphere. 2018;2(5):e149.
   PubMed Web of Science ®Google Scholar
• Eikeland SA, Smeland KB, Mols F, et al. Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin’s lymphoma; symptom burden and quality of life. Acta Oncol. 2021;60(7):911–920.
   PubMed Web of Science ®Google Scholar
• Murbraech K, Smeland KB, Holte H, et al. Heart failure and asymptomatic left ventricular systolic dysfunction in lymphoma survivors treated with autologous stem-cell transplantation: a national cross-sectional study. J Clin Oncol. 2015;33(24):2683–2691.
   PubMed Web of Science ®Google Scholar
• Smeland KB, Loge JH, Aass HCD, et al. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. Bone Marrow Transplant. 2019;54(4):607–610.
   PubMed Web of Science ®Google Scholar
• Sangha O, Stucki G, Liang MH, et al. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156–163.
   PubMed Web of Science ®Google Scholar
• Ware JE, Gandek B. Overview of the SF-36 health survey and the International Quality of Life Assessment (IQOLA) project: translating functional health and well-being: International Quality of Life Assessment (IQOLA) project studies of the SF-36 health survey. J Clin Epidemiol. 1998;51(11):903–912.
   PubMed Web of Science ®Google Scholar
• Leiknes KA, Dalsbø TK, Siqveland J. Måleegenskaper ved den norske versjonen av Hospital Anxiety and Depression Scale (HADS). Oslo: Norwegian Institute of Public Health; 2016.
   Google Scholar
• Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
   PubMed Web of Science ®Google Scholar
• Hansson M, Chotai J, Nordstom A, et al. Comparison of two self-rating scales to detect depression: HADS and PHQ-9. Br J Gen Pract. 2009;59(566):e283–e288.
   PubMed Web of Science ®Google Scholar
• Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147–153.
   PubMed Web of Science ®Google Scholar
• NTNU. Retningslinjer for publisering av forskningsresultater som bruker HUNT-data. Norges teknisk-naturvitenskapelige universitet; u.å. [cited 2021 Nov 9]. Available from: https://www.ntnu.edu/documents/140075/1295406997/Retningslinjer_for_publisering_av_forskningsresultater_som_bruker_HUNT_data.pdf/b8a25728-8c00-50b1-2901-43d5025e9d71?t=1600862719714
   Google Scholar
• Dahl AA, Grotmol KS, Hjermstad MJ, et al. Norwegian reference data on the Fatigue Questionnaire and the Patient Health Questionnaire-9 and their interrelationship. Ann Gen Psychiatry. 2020;19(1):60.
   PubMed Web of Science ®Google Scholar
• Jacobsen EL, Bye A, Aass N, et al. Norwegian reference values for the Short-Form Health Survey 36: development over time. Qual Life Res. 2018;27(5):1201–1212.
   PubMed Web of Science ®Google Scholar
• Raut M, Singh G, Hiscock I, et al. A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma. Expert Rev Hematol. 2022;15(7):607–617.
   PubMed Web of Science ®Google Scholar
• Linch DC, Goldstone AH, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071.
   PubMed Web of Science ®Google Scholar
• Brandt J, Dietrich S, Meissner J, et al. Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Leuk Lymphoma. 2010;51(11):2012–2020.
   PubMed Web of Science ®Google Scholar
• Mols F, Vingerhoets AJJM, Coebergh JW, et al. Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer. 2006;42(16):2794–2801.
   PubMed Web of Science ®Google Scholar
• Kreissl S, Müller H, Goergen H, et al. Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin Study Group. J Clin Oncol. 2020;38(25):2839–2848.
   PubMed Web of Science ®Google Scholar
• Kreissl SMD, Mueller HP, Goergen HD-M, et al. Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. 2016;17(10):1453–1462.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• Øvlisen AK, Jakobsen LH, Kragholm KH, et al. Depression and anxiety in Hodgkin lymphoma patients: a Danish nationwide cohort study of 945 patients. Cancer Med. 2020;9(12):4395–4404.
   PubMed Web of Science ®Google Scholar
• Glimelius I, Ekberg S, Linderoth J, et al. Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time—a population-based comparative study. J Cancer Surviv. 2015;9(4):599–609.
   PubMed Web of Science ®Google Scholar
• Myers RM, Hill BT, Shaw BE, et al. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. Cancer. 2018;124(4):816–825.
   PubMed Web of Science ®Google Scholar
• Borchmann P. Caring beyond cure: quality of life after high-dose chemotherapy for patients with relapsed Hodgkin lymphoma. Leuk Lymphoma. 2010;51(11):1949–1950.
   PubMed Web of Science ®Google Scholar
• Behringer K, Goergen H, Müller H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: the impact on treatment outcome and social reintegration. J Clin Oncol. 2016;34(36):4329–4337.
   PubMed Web of Science ®Google Scholar
• Eikeland SA, Smeland KB, Simensen VC, et al. Chronic fatigue in long-term survivors of Hodgkin’s lymphoma after contemporary risk-adapted treatment. Acta Oncol. 2023;62(1):80–88.
   PubMed Web of Science ®Google Scholar
• Franceschetti S, Annunziata MA, Agostinelli G, et al. Late neurological and cognitive sequelae and long-term monitoring of classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a systematic review by the fondazione italiana linfomi. Cancers. 2021;13(14):3401.
   PubMed Web of Science ®Google Scholar
• Williams AM, Xing M, Mirzaei Salehabadi S, et al. Prevalence and predictors of neurocognitive ­impairment in Long-Term survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. Blood. 2020;136(Supplement 1):14–15.
   Google Scholar
• Trachtenberg E, Mashiach T, Ben Hayun R, et al. Cognitive impairment in Hodgkin lymphoma survivors. Br J Haematol. 2018;182(5):670–678.
   PubMed Web of Science ®Google Scholar
• Folkehelseinstituttet. Alkoholbruk i den voksne befolkningen: Folkehelseinstituttet; 2022 [updated 2022 Jan 4; cited 2022 Oct 13]. Available from: https://www.fhi.no/nettpub/alkoholinorge/omsetning-og-bruk/alkoholbruk-i-den-voksne-befolkningen/
   Google Scholar